Improvement in natural erections has been reported in approximately 9% of impotent men using intracavernous injections of vasoactive drugs for erection induction. The mechanisms which may account for this improvement are psychogenic, improved cavernous hemodynamics, prostaglandin-induced angiogenesis, improved cavernous oxygenation, cavernous smooth muscle hypertrophy and/or normal episodic¯uctuations in erectile function. A review of the basic science literature on this subject reveals several theoretical explanations for this phenomenon but a review of the clinical literature reveals little convincing evidence that physiologic and/or pharmacologic factors are responsible for improvement in natural erections with intracavernous injection therapy. Furthermore, the prevalence of a placebo effect from impotence therapy exceeds the reported rate of improvement in natural or spontaneous erections. The most plausible explanations for spontaneous improvement in erections during or after intracavernous injection therapy are psychogenic and episodic variations in erectile function, rather than physiologic or pharmacologic factors. However, intracavernous injection therapy started soon after radical prostatectomy may have a protective effect in preserving normal cavernous physiology and erectile function in men being treated for prostate cancer.
Introduction
Improvement in natural or spontaneous erections has been reported to occur in impotent men who use intracavernous injections of papaverine, phentolamine and/or prostaglandin E1 for erection induction. A review of the urological literature of the past 10 y revealed 15 publications in which this phenomenon was recorded statistically. Of the total of 2817 patients in these 15 reports, 259 or 9.2% (range 2±37%) achieved natural erections and no longer required any injections (Table 1) . Additionally, 446 of 1526 evaluable patients or 29.2% (range 1±50%) reported reduction in the frequency or dose of injections needed to achieve satisfactory sexual function (Table 1) .
Why does this phenomenon happen? Is the occurrence of improved natural erections with intracavernous injection therapy solely a psychological effect or are there physiologic and/or pharmacologic changes which result in improved erectile function? What are the mechanisms by which improvement in natural erectile function might occur during or after intracavernous injection therapy?
Possible mechanisms of improved erectile function
There are several mechanisms which may account for the improvement in erectile function which sometimes occurs during or after intracavernous injection therapy. These mechanisms include:
(1) Psychological effect, for example relief of performance anxiety. (2) Improved cavernous hemodynamic responses resulting from mechanical dilatation of cavernous arteries and/or mechanical stretching of cavernous and tunical tissues. This, in turn, may produce improvement in tissue compliance and corporovenous occlusive ef®ciency. 
Laboratory research
Data available from laboratory research form the basis for postulating that smooth muscle hypertrophy and neovascularity induced by prostaglandin E1 injections may contribute to improvement in erectile function from self-injection therapy. Two studies have shown that smooth muscle hypertrophy may develop in the corpora cavernosa of monkeys given intracavernous injections. Aboseif et al 1 found that marked smooth muscle hypertrophy of the corpora cavernosa occurred with intracavernous papaverine injections while only minimal hypertrophy occurred with prostaglandin injections. The hypertrophic response to papaverine was also associated with smooth muscle atrophy and ®brosis in other areas of the corpora cavernosa. Normal muscle architecture of the cavernous tissue was preserved with prostaglandin injections. Hwang et al 2 found in monkeys that intracavernous papaverine injections produced mitochondrial aggregation and cell atrophy while intracavernous prostaglandin injections produced smooth muscle hypertrophy. While these two studies found different results from papaverine and prostaglandin injections, both identi®ed that smooth muscle hypertrophy may result from intracavernous injections of these vasoactive substances. These papers raise the possibility that smooth muscle hypertrophy occurs in some men following chronic self-injection therapy. This hypertrophy may enhance the ef®ciency of cavernous physiology, producing improved natural erections.
In another pertinent research study, Spisni et al 3 investigated the incorporation of radiolabelled sulfate into the capillaries of chick embryo chorioallantoic membranes. They found that prostaglandin E1 administration caused a signi®cant increase in the number of capillaries in these membranes. This study supports the concept that prostaglandin injection may produce improved natural erections by inducing angiogenesis and neovascularity of the cavernous tissue.
Clinical research studies
Several clinical research studies are pertinent to understanding the phenomenon of improved natural erectile function with intracavernous injection therapy.
The largest study of the longterm effects of intracavernous injection therapy is that of Virag et al. 4 These authors reported on 533 patients followed while on intracavernous injection therapy with papaverine alone, a combination of papaverine with alpha blockers, or a six drug combination. Of the total group, 27.5% were classi®ed etiologically before treatment as psychogenic, 25.2% as organic and 47.3% as mixed psychogenic and organic impotence. Of the entire group of patients followed while on therapy, 7.8% stopped using intracavernous injections and were considered`cured' and 7.2% maintained good natural erectile function by monthly maintenance' intracavernous injections. Another 49% of the patients were partially dependent on self-injection therapy, requiring only occasional injections to maintain adequate sexual function. It is notable that the percentage of psychogenic etiology in the signi®cantly improved group was higher than in the total group (39.3% vs 27.5%) and the percentage of organic etiology was lower in the improved group than in the total group (18 vs 25.2%). The age of the improved group was younger than the total group (38 y vs 48 y). These data suggest weakly that signi®cant improvement in natural erections following intracavernous injection therapy is more likely to occur in younger men with psychogenic etiology of impotence.
Marshall et al 5 have developed clinical evidence which supports the concept that improvement in natural erections with self-injection therapy is due to improved penile hemodynamics. They compared 35 patients with arteriogenic and/or venogenic impotence treated with intracavernous injections of prostaglandin alone or a combination of prostaglandin, phentolamine and papaverine to 10 patients with arteriogenic and/or venogenic impotence who were not treated at all. They found that there was no difference by duplex sonography in cavernous artery diameter between the two groups either before or after therapy. However, chronic selfinjection therapy resulted in a very signi®cant increase in the cavernous artery peak¯ow velocity as measured by duplex sonography. In the treatment group, peak¯ow velocity increased from 19.5 cm/s before treatment to 26.5 cm/s after treatment, a 35% increase. In the untreated controls, the peak¯ow velocity during the observation period did not change signi®cantly. Simultaneous with the increased arterial peak¯ow velocity, 13 of the 35 treated subjects (37%) reported that they experienced good functional natural erections without the use of intracavernous injections and 19 of the 35 subjects (54%) experienced an improvement in the quality or quantity of their erections achieved without injection. None of the untreated control group experienced functional natural erections. Therefore this study suggests that the development of functional natural erections may be attributed to improved penile hemodynamics. However, it should be clearly noted that there was no difference in the arterial peak¯ow velocity in the 13 patients who experienced functional natural erections compared to the 22 patients who did not experience functional natural erections. Therefore, the measured improvement in arterial peak¯ow velocity may not have been responsible for the improved erectile function.
A large retrospective study of patients who claimed`cure' of impotence from intracavernous injection therapy was reported by Basile et al. 6 They sent questionnaires to 921 patients on chronic selfinjection therapy and received responses from 387 patients. The responses occurred after an average of about 13 months of self-injection therapy and an average of 55 injections. These investigators found that 6% no longer needed self-injection therapy, 15% needed injections less often, 17% needed a smaller dose and 22% experienced improved quality of natural or spontaneous erections. They found that the improvement in erectile function correlated only to younger age but not to any other clinical parameters, including blood pressure, cholesterol levels, smoking history, or the presence or absence of heart disease and diabetes.
A very well-designed study on the return of spontaneous erections with prostaglandin E1 selfinjections by McMahon 7 addressed the psychological aspect of this phenomenon. McMahon compared 153 self-injection treated men with arteriogenic, venogenic and/or psychogenic impotence to 53 untreated controls with the same etiologies of impotence. He found that 9% of the treated men with vasculogenic impotence experienced spontaneous natural erections six months after initiation of self-injection therapy while 10±12% of the untreated men with vasculogenic impotence also experienced spontaneous erections when evaluated six months later. However, there was a major difference due to treatment in the men with psychogenic impotence. Of the 37 men with psychogenic impotence who received self-injection therapy for six months, 84% experienced spontaneous natural erections. Of the 18 men with psychogenic impotence who were not treated, 22% experienced spontaneous erections. McMahon concluded that restoration of erections by injection therapy occurs predominantly in patients with psychogenic impotence. This study strongly suggests a psychogenic mechanism for this phenomenon.
Two very recent studies concerning post-radical prostatectomy patients are also pertinent to the possibility that intracavernous injection of prostaglandin may result in improved natural erections. Montorsi et al 8 studied 30 men whose sexual function was normal before radical retropubic prostatectomy. Fifteen of these men were treated with intracavernous Alprostadil three times weekly starting one month after surgery. Fifteen men were observed without intracavernous therapy. After six months, three patients dropped out of the treatment group but eight of the remaining 12 (67%) reported progressive return of spontaneous erections. In the observation group, only three of the 15 men (20%) regained spontaneous erections.
Padma-Nathan et al 9 followed 40 men who had normal erections before radical prostatectomy. These men self-injected Caverject intracavernously at home for 12 weeks starting at variable times after radical prostatectomy. Of 31 men who completed the study, 22 (71%) reported return of spontaneous erections. While there was no control group in this study, the authors compared these results to à historical control' rate of 20% for return of spontaneous erections. In those men who began intracavernous therapy less than 300 d after surgery, 16 of the 22 (73%) experienced return of erections. In those men who began intracavernous therapy more than 300 d after surgery, only six of the 17 (35%) experienced return of erections.
These two studies suggest that a pharmacologic effect of intracavernous prostaglandin therapy after radical prostectomy enhances the chance for return of spontaneous erections. However, the improved chances for natural erections in these men may also be due to factors other than the pharmacologic effect of prostaglandin, such as greater interest, attention or motivation concerning sexual function in the treated men or simply the psychogenic effect of active therapy.
The magnitude of the psychogenic or placebo effect of therapy for erectile dysfunction must be considered in assessing the relationship of intracavernous therapy to spontaneous erections. It is clear from recent data on new oral and topical therapies for impotence that a placebo effect of any therapy occurs in approximately 20±40% of cases.
10±12 This high rate of placebo effect may be due to the inaccuracy of diagnostic tests in eliminating patients with psychogenic erectile dysfunction from drug study groups and surgical series. Assuming a 20% baseline placebo effect of any therapy for erectile dysfunction, proof of ef®cacy of therapy for impotence requires success of greater than 20%.
Conclusions
From this review of the literature, it is not possible to identify de®nitively whether improved natural erections result from intracavernous injection therapy in men with chronic impotence. The average prevalence of such improvement is about 9% in the literature reviewed. The prevalence of a placebo effect from any therapy for impotence seems to exceed this. True physiologic and/or pharmacologic explanations for improvement of impotence from intracavernous injection therapy probably occur infrequently. When spontaneous improvement does occur following intracavernous therapy in men with chronic impotence, the most plausible explanations are psychogenic factors and coincidental¯uctua-tions in erectile function due to variations in stress, general health, medications and/or partner factors.
Intracavernous injection therapy started soon after radical prostatectomy may have a protective effect in preserving erectile function in men with normal preoperative erections. Further studies are needed to con®rm this concept in post-prostatectomy patients.
